Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2016—Horizon Discovery Group introduced its cell-free DNA (cfDNA) HDx Reference Standards. The reference standards enable researchers to demonstrate the performance of their cfDNA assays by providing a reproducible, consistent, and reliable source of reference material for their development and evaluation.
January 2016—Beckman Coulter Diagnostics launched its Cystatin C assay for the company’s AU clinical low- to ultra-high-volume family of chemistry systems and Immage 800 immunochemistry systems.
January 2016—Worthington Biochemical announced distribution rights to the Celase GMP compliant enzyme from Cytori Therapeutics. The Celase GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.
January 2016—Instrumentation Laboratory announced the 510(k) clearance of its ACL TOP Family 50 Series Hemostasis Testing Systems. Designed for mid- to high-volume clinical laboratories, including those using lab automation tracks, the ACL TOP Family 50 Series systems, comprising five models, offer preanalytical quality assurance, risk-management, and laboratory accreditation benefits.
January 2016—Bio SB introduced Helicobacter Pylori, MMab, Clone: BSB-37, a new line of mouse monoclonal antibodies for IHC with extensive protein immunogenicity analysis of targeted epitopes, high sensitivity specificity, and low background noise.
January 2016—Enzo Life Sciences launched a VEGF ELISA kit that provides a quantitative, competitive detection method for measuring melatonin in serum, plasma, and cell culture supernants.
January 2016—Swift Biosciences will incorporate Horizon Discovery Group’s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.
January 2016—T2 Biosystems presented data at the AMP annual meeting on its investigational T2Bacteria Panel. The data demonstrate the ability of T2Bacteria to provide rapid and sensitive identification of six sepsis-causing bacteria, directly from whole blood, with limits of detection as low as 1 CFU/mL.
January 2016—Agena Bioscience announced the planned commercial launch of its CE-IVD marked MassArray Dx Plus assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics.
January 2016—BioMérieux and Illumina announced the launch of BioMérieux EpiSeq, a next-generation sequencing service dedicated to the epidemiological monitoring and control of health care–associated infections. The EpiSeq service is the first result of the collaboration agreement signed by the two companies in November 2014.
